What type of study is this?

This is a Systematic Review study.

December 8, 2025Blood

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis showed low overall survival in patients with MDS-f treated with hypomethylating agents, indicating poor prognosis.

Overall survival is reduced to 18.9 months in patients with MDS-f receiving hypomethylating agents.
Patients with MDS-IB show a superior overall response rate of 51% compared to 35.4% in MDS-f.
The study assessed treatment-emergent grade IV neutropenia and thrombocytopenia in the MDS-f cohort, with rates at 73.2% and 55.6%, respectively.
Incorporation of Venetoclax in HMA therapy did not change survival outcomes in MDS-f compared to MDS-IB patients.

Ali et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark